Rocuronium bromide
DrugRocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
Other names: Rocuronium Bromide Fresenius Kabi
NCT Number: NCT02376595
The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
Other names: Rocuronium Bromide Fresenius Kabi
Time frame: 60 minutes
Time frame: 120 minutes
Pontificia Universidad Catolica de Chile
Other
Pharmacokinetic and Pharmacodynamic of Rocuronium Bromide Measured in Adductor Pollicis and Masseter Muscles.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06220136
Anesthesia, General, Neuromuscular Blockade
Ankara, Altındağ, Turkey (Türkiye)
View Trial DetailsNCT07580144
Atrophy, Frailty
Konya, Turkey (Türkiye)
View Trial DetailsNCT05006807
Neuromuscular Blockade
Seattle, Washington, United States
View Trial DetailsNCT07404579
Neuromuscular Blockade
Zhengzhou, Henan, China
View Trial Details